This is an aggregated industry headline. Read the full story at FierceBiotech →
FDA halts release of new drug rejection letters while working to formalize policy
The FDA has paused a controversial policy of releasing letters describing its rationale for rejecting drugs, Fierce Biotech has learned, following a citizen's petition from an unnamed pharma company in April.
By FierceBiotech
· Jul 9, 2026
· via FierceBiotech
RxInsider combines reported facts with industry analysis and informed inference. Forward-looking reads, market commentary, and interpretive framing reflect analysis of available reporting and known facts, not confirmed outcomes.
Tags
theweekformat:headlineheadlineFierceBiotech
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.
More from The Week
All The Week →
The WeekFiercePharma ↗
Allergan Aesthetics on Tuesday welcomed Girls Inc. participants to a panel and tour at its Allergan Medical In…
The WeekBriefing
The newly approved Dexcom Stelo continuous glucose monitor opens access beyond diabetes management, prompting …
The WeekSTAT News ↗
Two years, six months, and 18 days have elapsed since Northwest Biotherapeutics submitted its brain cancer tre…